



22 September 2017

ASX Announcement / Media Release

Updated Investment Research Report

22 September 2017, Perth, Australia: Race Oncology Limited (ASX: RAC) today announced the publication of an updated commissioned report on Race Oncology by research house, Independent Investment Research (IIR).

The updated IIR report is available on the Company's website at: www.raceoncology.com

About Race Oncology (RAC. ASX)

Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is a chemotherapy drug, Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s, then lost in a series of pharma mergers.

For more information, contact:

Peter Molloy

Managing Director

T: +61 (0) 3 9097 1656

M: +61 (0) 418 174 816